BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18782796)

  • 1. Commentary on drug-eluting stents: to use or not to use--that is the question!
    Pfisterer ME
    Heart; 2008 Dec; 94(12):1648-50. PubMed ID: 18782796
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary on drug-eluting stents: NICE technology appraisal guidance.
    Richardson J; Stevens A; Barnett D; Longson C
    Heart; 2008 Dec; 94(12):1650-2. PubMed ID: 18768567
    [No Abstract]   [Full Text] [Related]  

  • 3. NICE guidelines for the use of drug-eluting stents: how do we establish worth?
    de Belder MA;
    Heart; 2008 Dec; 94(12):1646-8. PubMed ID: 18728067
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidance.
    Messori A; Trippoli S
    Heart; 2009 May; 95(10):847. PubMed ID: 19401286
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NICE, drug-eluting stents and the limits of trial data.
    Mohindra R
    Heart; 2009 Mar; 95(6):505-6; author reply 506. PubMed ID: 19252009
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug-eluting stents: costs versus clinical benefit.
    O'Neill WW; Leon MB
    Circulation; 2003 Jun; 107(24):3008-11. PubMed ID: 12821587
    [No Abstract]   [Full Text] [Related]  

  • 8. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting stents: cost versus clinical benefit.
    Lemos PA; Serruys PW; Sousa JE
    Circulation; 2003 Jun; 107(24):3003-7. PubMed ID: 12821586
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug-eluting coronary stents and drug eluting balloon catheters: summary of the position papers of the DGK].
    Silber S; Borggrefe M; Böhm M; Hoffmeister HM; Dietz R; Ertl G; Heusch G
    Clin Res Cardiol; 2008 Aug; 97(8):548-63. PubMed ID: 18726643
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcome observations with drug-eluting stents.
    Steffenino G; Olivari Z
    J Cardiovasc Med (Hagerstown); 2008 Feb; 9(2):110-2. PubMed ID: 18192800
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: three-year follow-up results from a single institution.
    Li Y; Zheng Z; Xu B; Zhang S; Li W; Gao R; Hu S
    Circulation; 2009 Apr; 119(15):2040-50. PubMed ID: 19349321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary artery restenosis: a paradigm of current treatment approaches.
    Kiernan TJ; Kiernan GD; Yan BD
    Minerva Cardioangiol; 2009 Feb; 57(1):77-94. PubMed ID: 19202520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late in-stent restenosis in a patient with drug-eluting stent.
    Sultan FA; Kazmi K; Dhakam S; Quraishi AU
    J Coll Physicians Surg Pak; 2005 Oct; 15(10):648-9. PubMed ID: 19810309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The high cost of nonadherence after percutaneous coronary intervention--can health care reform solve this problem?
    Mukherjee D
    Am Heart J; 2009 Oct; 158(4):506-8. PubMed ID: 19781406
    [No Abstract]   [Full Text] [Related]  

  • 17. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting stents are safe.
    Garg S; Serruys P
    Clin Pharmacol Ther; 2009 Aug; 86(2):130-2. PubMed ID: 19621006
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-eluting stents are here--now what? Implications for clinical practice and health care costs.
    Hirshfeld JW; Wilensky RL
    Cleve Clin J Med; 2004 Oct; 71(10):825-8. PubMed ID: 15529488
    [No Abstract]   [Full Text] [Related]  

  • 20. Are drug eluting stents really worth the money?
    Thomas M
    Heart; 2006 Jan; 92(1):5-7. PubMed ID: 15939723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.